- Home
- STTK vs LEGT Comparison
STTK vs LEGT Comparison
Compare STTK & LEGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STTK | LEGT |
|---|---|---|
| Founded | 2016 | 2023 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.9M | 282.2M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | STTK | LEGT |
|---|---|---|
| Price | $5.99 | $10.94 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 574.2K | 88.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $35.64 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.69 | $10.44 |
| 52 Week High | $6.13 | $11.50 |
Technical Indicators
Market Signals| Indicator | STTK | LEGT |
|---|---|---|
| Relative Strength Index (RSI) | 72.78 | 49.89 |
| Support Level | $1.85 | $10.84 |
| Resistance Level | N/A | $10.95 |
| Average True Range (ATR) | 0.40 | 0.05 |
| MACD | 0.17 | -0.00 |
| Stochastic Oscillator | 89.34 | 15.79 |
Price Performance
Historical ComparisonAbout STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About LEGT Legato Merger Corp. III
Legato Merger Corp III is a blank check company.